GB2451451A - Osteogenic compounds - Google Patents
Osteogenic compounds Download PDFInfo
- Publication number
- GB2451451A GB2451451A GB0714791A GB0714791A GB2451451A GB 2451451 A GB2451451 A GB 2451451A GB 0714791 A GB0714791 A GB 0714791A GB 0714791 A GB0714791 A GB 0714791A GB 2451451 A GB2451451 A GB 2451451A
- Authority
- GB
- United Kingdom
- Prior art keywords
- poly
- polymer
- lactide
- composition
- bmp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 64
- 230000002188 osteogenic effect Effects 0.000 title claims description 17
- 239000000203 mixture Substances 0.000 claims abstract description 73
- 229920000642 polymer Polymers 0.000 claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 32
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 230000001737 promoting effect Effects 0.000 claims abstract description 4
- 239000011159 matrix material Substances 0.000 claims description 30
- 229920001577 copolymer Polymers 0.000 claims description 26
- -1 po].ycapro].actones Polymers 0.000 claims description 23
- 239000007943 implant Substances 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 17
- 229940002612 prodrug Drugs 0.000 claims description 16
- 239000000651 prodrug Substances 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 10
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 10
- 208000010392 Bone Fractures Diseases 0.000 claims description 9
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 9
- 239000005977 Ethylene Substances 0.000 claims description 9
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 8
- 229920000954 Polyglycolide Polymers 0.000 claims description 7
- 238000012545 processing Methods 0.000 claims description 7
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 6
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 claims description 6
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 6
- 229920001281 polyalkylene Polymers 0.000 claims description 6
- 229920002959 polymer blend Polymers 0.000 claims description 6
- 229920001897 terpolymer Polymers 0.000 claims description 6
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 5
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 claims description 5
- 102000045896 human BMP2 Human genes 0.000 claims description 5
- 230000011164 ossification Effects 0.000 claims description 5
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims description 5
- 229920001610 polycaprolactone Polymers 0.000 claims description 5
- 239000000622 polydioxanone Substances 0.000 claims description 5
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims description 4
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 claims description 4
- 101001023988 Homo sapiens Growth/differentiation factor 5 Proteins 0.000 claims description 4
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 4
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims description 3
- 229920001710 Polyorthoester Polymers 0.000 claims description 3
- 108091005573 modified proteins Chemical class 0.000 claims description 3
- 102000035118 modified proteins Human genes 0.000 claims description 3
- 150000003891 oxalate salts Chemical class 0.000 claims description 3
- 239000005015 poly(hydroxybutyrate) Substances 0.000 claims description 3
- 229920000141 poly(maleic anhydride) Polymers 0.000 claims description 3
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 3
- 239000004632 polycaprolactone Substances 0.000 claims description 3
- 229920002721 polycyanoacrylate Polymers 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 150000003890 succinate salts Chemical class 0.000 claims description 3
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 claims description 2
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 2
- 108010090254 Growth Differentiation Factor 5 Proteins 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 238000010348 incorporation Methods 0.000 claims description 2
- 238000010128 melt processing Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229920001245 poly(D,L-lactide-co-caprolactone) Polymers 0.000 claims description 2
- 229920000218 poly(hydroxyvalerate) Polymers 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 239000004417 polycarbonate Substances 0.000 claims description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims 5
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims 2
- 239000004952 Polyamide Substances 0.000 claims 2
- 229920002732 Polyanhydride Polymers 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 229920001308 poly(aminoacid) Polymers 0.000 claims 2
- 229920001072 poly(l-lactide-co-caprolactone) Polymers 0.000 claims 2
- 229920002647 polyamide Polymers 0.000 claims 2
- 229920006149 polyester-amide block copolymer Polymers 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 229920002635 polyurethane Polymers 0.000 claims 2
- 239000004814 polyurethane Substances 0.000 claims 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 235000011090 malic acid Nutrition 0.000 claims 1
- 239000001630 malic acid Substances 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 23
- 230000008439 repair process Effects 0.000 abstract description 9
- 150000003951 lactams Chemical class 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 17
- 239000012528 membrane Substances 0.000 description 13
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 12
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 12
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 10
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 10
- 230000035876 healing Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229940125904 compound 1 Drugs 0.000 description 6
- 229940125782 compound 2 Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 241001529936 Murinae Species 0.000 description 5
- 108010043267 Sp7 Transcription Factor Proteins 0.000 description 5
- 102100032317 Transcription factor Sp7 Human genes 0.000 description 5
- 229940126214 compound 3 Drugs 0.000 description 5
- 208000006670 Multiple fractures Diseases 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- CJYXCQLOZNIMFP-UHFFFAOYSA-N azocan-2-one Chemical compound O=C1CCCCCCN1 CJYXCQLOZNIMFP-UHFFFAOYSA-N 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000003239 periodontal effect Effects 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108091092584 GDNA Proteins 0.000 description 2
- QISSLHPKTCLLDL-UHFFFAOYSA-N N-Acetylcaprolactam Chemical compound CC(=O)N1CCCCCC1=O QISSLHPKTCLLDL-UHFFFAOYSA-N 0.000 description 2
- ZWXPDGCFMMFNRW-UHFFFAOYSA-N N-methylcaprolactam Chemical compound CN1CCCCCC1=O ZWXPDGCFMMFNRW-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229940124532 absorption promoter Drugs 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000008468 bone growth Effects 0.000 description 2
- 230000010478 bone regeneration Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012909 foetal bovine serum Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 101150061927 BMP2 gene Proteins 0.000 description 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 244000078639 Mentha spicata Species 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000005313 bioactive glass Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Inorganic materials [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- ZOMBKNNSYQHRCA-UHFFFAOYSA-J calcium sulfate hemihydrate Chemical compound O.[Ca+2].[Ca+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O ZOMBKNNSYQHRCA-UHFFFAOYSA-J 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 239000011507 gypsum plaster Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 230000000278 osteoconductive effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
A family of lactams, as defined therein, compositions comprising said family of compounds, the use of these compounds and compositions for promoting bone regrowth and repair. Also disclosed are methods for manufacturing such compositions in the form of, for example, resorbable polymer matrices containing the compounds.
Description
OSTEOGENIC COMPOUNDS
Technical field
The present invention relates to compounds having osteogenic properties, uses of said compounds, compositions comprising those compounds, methods of manufacturing compositions and methods useful in bone repair.
Background of the Invention
Most people will have broken or will break a bone in their body during their lifetime. With an ever ageing population the incidence of broken bones is only likely to increase.
The traditional method for fixing broken bones includes repositioning the broken bone in the correct position and applying plaster of Paris or fibreglass to the outside of the limb concerned in order to form a cast'. Once the bone has set the cast may be removed.
More recently developed methods include the fitting of bone plates with screws and the like to keep the broken bone in position while healing occurs. One such method is described in US 7,122,037. Another method involves the positioning of a resorbable polymer composition around the broken bone which composition holds the bone in position while healing occurs and then slowly dissolves and is absorbed by the body of the patient as taught in Us 6,607,548.
The process of bone healing is relatively poorly understood.
The present knowledge is that osteoinductjon occurs via growth factors, in particular bone morphogenic protein (BMP) which induces undifferentiated mesenchymal cells to congregate at the point of the break and differentiate into osteoblasts which effect repair of the break.
What is also known, however, is that several rather diverse methods are available to enhance bone growth, such as mechanical stimulation, electromagnetic fields, low-intensity ultrasound, osteoconductive materials, for instance hydroxyapatite, tricalcium phosphate, bioactive glass etc., and osteoinductjve materials, such as growth factors.
US 6,926,903 teaches the use of resorbable polymer compositions comprising a compound which infers osteogenic properties to the composition. This type of composition gives the advantage that whilst holding the broken bone in place for healing, the oestogenic compound may slowly release from the composition causing bone growth rate to increase at the site of the break. Such compositions can result in significantly faster bone healing.
It would be useful if other osteogenic compounds were available that showed a similar or improved effect.
It is an object of the invention to provide alternative osteogenic compounds for use in bone repair or at least to provide the public and/or medical community with a useful alternative.
Various compounds and uses for compounds according to the invention are detailed in the accompanying specification.
These compounds and their uses are to be considered exemplification only and are not to be construed as limiting the scope of the invention as defined by the appended claims.
Summary of the Invention
The present invention relates to compounds, compositions and the use of these compounds and compositions for promoting bone regrowth and repair, to methods for manufacturing such compositions and to methods of treating patients with broken bones.
Accordingly, there is provided, in a first aspect of the invention a compound according to figure I $0 Figure I wherein R is selected from H, methyl and acetyl; and X is methylene or ethylene; and its pharmaceutically acceptable salts and prodrugs for use as a medicamerit.
Pharmaceutically acceptable salts and prodrugs may be of any type so long as when administered to a patient an appreciable portion of the free drug becomes available. In some embodiments salts may be those of inorganic acids such as suiphates and chlorides.
In preferred embodiments the compound is the compound according to formula I wherein X is methylene and R is hydrogen or methyl.
In another preferred embodiment the compound is the compound according to formula I wherein X is ethylene and R is acety]..
In a second aspect the invention provides a resorbable polymer composition comprising a polymer matrix and a compound according to figure I Figure I wherein R is selected from H, methyl and acetyl; and X is methylene or ethylene; its pharmaceutically acceptable salts or prodrugs.
The polymer matrix may be selected from the group consisting of polyg].ycolide, polylactides, polycaprolactones, polytrinlethylenecarbonates polyhydroxybutyrates, polyhydroxyvalerates, polydioxanoneg, polyorthoesters, polycarbonates, polytyrosinecarbonates, polyorthocarbonates polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(maleic anhydride), polypeptides, polydepsipeptideg, polyvinyla].cohol, polyesteramjdeg, po].yamides, polyanhydrjdes, polyurethaneg, polyphosphazenes, polycyanoacrylates, polyfumarates, po].y (amino acids), modified polysaccharjdes, modified proteins and their copolymers, terpolymers or combinations or mixtures or polymer blends thereof.
In preferred embodiments the polymer matrix is selected from the group consisting of polyglycolide, poly(L-lactjde-co-glycolide), poly(D, L-lactide-co-g].ycoljde) poly(L-lactide), poly(DL-lactjde), poly(L-lactidecoD,L_1actjde), polycaprolactone, poly(L-].actide-cocapro1actofle) poly(D, L- lactide-co-caprolactone) pOlytrimethy].enecarbonate poly(L- lactide-co-trjmethylenecarbonate) poly(D, L-lactjde-co-trimethylerlecarbonate), polydioxanone and their copolymers, terpolymers or combinations or mixtures or polymer blends thereof.
In particularly preferred embodiments the polymer matrix comprises carbonate copolymer (PLAJPGA/TMC) with a composition of 80/10/10, Poly D, L-lactide/Poly L-lactide/Trjmethylene carbonate copolymer (PLDL/PI./C) with a composition of 55/40/5, or a matrix comprising 80 wt-% P(L/DL)L. (70/30) and 20 wt-% PLLA/TMC (70/30) The resorbable polymer composition may contain anywhere between the minimal amount of the compound of formula I, its pharmaceutically acceptable salts or prodrugs, required for a pharmaceutical effect up to about 50% by weight of the composition.
Preferably the resorbable polymer composition is in the form of an implant.
Preferably the compound of formula I, its pharmaceutically acceptable salts or prodrugs, make up between 0.05 and 50's by weight of the composition. More preferably the compound of formula I, its pharmaceutically acceptable salts or prodrugs, is present in an amount of between 0.]. and 10% by weight.
Preferably the compound of formula I, its pharmaceutically acceptable salts or prodrugs, are spread throughout the resorbab].e polymer matrix evenly but in some embodiments may be positioned only in that portion of the device intended to lie against the bone. In other embodiments the compound of formula I, its pharmaceutically acceptable salts or prodrugs, may have any distribution profile within the resorbable polymer composition.
In a third aspect the invention also provides the use a compound according to figure I Figure I wherein R is selected from H, methyl and acetyl; and X is methylene or ethylene; its pharmaceutically acceptable salts or prodrugs, in the manufacture of a medicament for promoting osteogenesis, particularly for assisting in the healing of, or treating, a fractured bone.
The medicament may be in any form such as tablet, capsule, slow release composition, powder for inhalation, syrup and any other form known in the art.
The meclicaments may be in the form of a mixture with any pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" includes a material which is not biologically or otherwise undesirable. Such a material may be administered to an individual along with the selected active agent without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.
The medicaments according to the invention may be manufactured using any methods known in the art. For example, the compositions may be dry milled and mixed prior to tableting and the composition may therefore necessarily contain other Pharmaceutically expectable excipients such as a lubricant selected from the group consisting of calcium stearate, magnesium stearate, zinc stearate, stearic acid, talc and combinations thereof, a binding agent selected from the group consisting of hydroxypropy].methyl cellulose, hydroxyethyl cellulose, hydroxypropy]. cellulose, methyl cellulose and a polyvinyl pyrrolidone (PvP).
Medicaments according to the invention may contain any pharmaceutically acceptable excipients such as binders, fillers, pigments, disintegrating agents, lubricants, wetting agents, buffers and other excipients conventionally used in the pharmaceutical and chemical fields. Some examples of excipients for use in the medicaments of the present invention are microcrystalline cellulose, lactose, starch, colloidal silica, talc, glycerol esters, sodium stearyl fumarate, and titanium dioxide.
For oral administration compositions or medicaments of the invention may be administered with any inert diluent or with an edible carrier. They may be incorporated directly into food or beverages making up part of the patient's diet. The compositions or medicaments of the invention may be formulated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspension syrups, wafers, and the like.
The tablets, troches, pills, capsules and the like may contain those excipients already mentioned and in some cases may also contain sweetening agents, such as sucrose, glucose, aspartame or saccharin, flavouring agents such as essential oils of mint, peppermint, spearmint or any other suitable flavouring. When the dosage unit is a capsule it may additionally contain a liquid carrier such as an oil or buffered aqueous solution.
Medicaments and compositions of the invention may also be formulated with phospholipids or fatty acids or other synthetic nanoparticles as carriers.
Medicaments and compositions of the invention may take the form of formulations for parentera]. administration and may include sterile aqueous solutions or dispersions, and sterile powders for the preparation of sterile, injectable solutions or dispersions. The solutions or dispersions may also contain buffers, diluents, and other suitable additives that may be designed to promote the cellular uptake of the active agents in the composition, for example, liposomes.
Pharmaceuticai formulations for topical administration may be especially useful for localized treatment. Formulations for topical treatment included ointments, sprays, gels, suspensions, lotions, creams, and the like. Formulations for topical administration may include known carrier materials such as isopropano]., glycerol, paraffin, stearyl alcohol, polyethylene glycol, and the like. The pharmaceutically acceptable carrier may also include a known chemical absorption promoter. Absorption promoters include, for example, trichioroethanol, trifluoroethanol, and certain alcohols and mixtures thereof according to GB 1,001,949 to Meyer and GB 1,464,975 to AstraLakemedel).
Medicaments and compositions of the invention suitable for rectal or vaginal administration may be presented as a suppository, which may include one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene g].ycol, a suppository wax or a salicylate, which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
The medicaments of the invention preferably comprise a resorbable polymer matrix, such as those exemplified herein.
In this embodiment the polymer matrix acts as a slow release composition in preferred embodiments1 allowing the compound of formula I, its pharmaceutically acceptable salts or prodrugs, to leach out of the resorbable composition over time and enhance bone repair.
In a fourth aspect the present invention provides a method for manufacturing an implant having osteogenic properties comprising the steps of; a) selecting polymer(s) or Copolymer(s); b) adding a compound according to figure I Figure I wherein R is selected from H, methyl and acetyl; and X is methylene or ethylene; its Pharmaceutically acceptable salts or prodrugs, in an amount of between 0.05 and 50 by weight; c) processing the polymer(s) or copolymer(s) to form a polymer matrix; and -li-d) forming the implant from said polymer matrix.
In a further aspect the present invention provides another method for manufacturing an implant having osteogenic properties comprising the steps of; a) selecting polymer(s) or copolymer(s); b) processing the polymer(s) or copolymer(s) to form a polymer matrix; C) forming the implant from said polymer matrix; and d) adding the implant to a solution of a compound according to figure I Figure I wherein R is selected from H, methyl and acetyl; and X is methylene or ethylene; its pharmaceutically acceptable salts or prodrugs, so that an amount of between 0.05 and 50% by weight is adsorbed by the implant.
The step of processing the polymer(s) or copolymer(s) to form a polymer matrix may be carried out by any means known to one of skill in the art. In preferred embodiments the processing step involves melt processing.
In one embodiment the method may involve incorporation of a compound of formula I, its pharmaceutically acceptable salts or prodrugs, into the polymer both prior to blending and after the implant is made.
The implant forms include, but are not limited to, membranes, films, plates, mesh plates, screws, taps or other formed pieces.
Without wishing to be bound by theory, the applicant believes that the osteogenic agents act in synergy with BMP and those other endogenous factors present that assist in bone repair, for example, BMP-2, BMP-4, BMP-7 and GDF-5.
Some aspects of the invention involve the inclusion of one or more of these endogenous factors within the formulation or polymer matrix so as to augment the naturally occurring factors which will be present at the site of a break. The invention therefore also encompasses those formulations, uses and methods where an endogenous factor and the osteogenic agent are present and/or administered in synergistic amounts. In one particularly preferred embodiment the osteogenic agent may be co-administered with one or more of recombinant human BMP-2, BMP-4, BMP-7 and GDF-5.
In a further aspect the present invention provides a method of treating a person in need of bone repair comprising administering a compound according to figure I Figure I wherein R is selected from H, methyl and acety].; and X is methylene or ethylene; its pharmaceutically acceptable salts or prodrugs, or a pharmaceutical composition according to the invention.
In preferred embodiments the method involves surgically implanting a resorbable polymer composition according to the invention.
In another preferred embodiment the medicament takes the form of a paste that may be applied between fractured portions of bone so as to provide a compound of formula I, its pharmaceutically acceptable salts or prodrugs, directly at the site of the break, thereby enhancing bone repair.
Certain aspects of the invention will now be exemplified.
The experiments detailed below are given by way of example only and are in no way intended to limit the scope of the invention as defined in the appended claims.
Methods Before the examples are introduced and discussed, the marker compounds monitored in the testing methods confirming the activity of the compounds of interest are briefly outlined.
3D Alkaline phosphatase is a commonly assessed biomarker associated with an osteogenic phenotype. Active osteoblasts robustly produce alkaline phosphatase, a chemical that has an essential role in making phosphate available for calcification of bone.
Osterix is a zinc finger-containing transcription factor that is essential for osteoblast differentiation and bone formation.
Examples
Example I -Cell culture and induction of differentiation Determination of alkaline phosphatase phenotype The murine muscle myoblast cell line, C2C12 (LotO5/K/031) was obtained from European Collection of Cell Cultures (Salisbury, U.K.). The cells were maintained in DMEM containing foetal bovine serum (10%), l-glutamine (2mM), penicillin G (lOOpg/mL) and streptomycin (lOOU/mL), in a humidified atmosphere containing 5% Co2 at 37°C.
To assess their differentiation into an osteogenic phenotype, C2C12 cells were seeded at a density of 0.5xlO4ce].ls/mL into polystyrene 96 well plates (Appleton Woods, Birmingham, U.K.) and maintained for 24 hours, after which they were treated with the three compounds of interest (detailed below) over a range of concentrations (5mM to 100pM) in the presence of subthreshold concentration of BMP- 2 (lOOng/mL; obtained from Prof. Franz Weber, University of Zurich); appropriate vehicle controls were used.
The compounds tested were: CH3 0 CH3 1 2 3 Compound 1 is n-methylcaprolactam, compound 2 is n- acetylcaprolactam and compound 3 is oenantholactam or 2-azacyclooctanone having CAS reference numbers 2556-73-2, 1888-91-1, and 673-66-5, respectively. In the examples and discussion that follow, the compounds will be referred to by their compound numbers detailed above.
A combination of BMP-2 (lOOng/mL) with NMP (5mM) -a compound found to have osteogenic properties -was used as a standard reference. Cells were maintained in culture for 7 days prior to assessment of alkaline phosphatase activity.
Results of the tests are shown below.
Assessment of Alkaline Phosphat:age activity Following 7 days in treatment, cell culture experiments were terminated by in situ lysis in Buffer A (containing 2-amino- 2-methylpropan1...o1 (0.56M; SigmaAldrjch, Poole, U.K.) and sodium dodecyl sulphate (0.1% w/V; SigmaA].drjch, Poole, U.K.) in H20, adjusted to pH 10 with 5N HC1); following two washes in PBS. Thereafter, 4-nitrophenyl phosphate (20mM in Buffer A containing MgC12 (4mM)) was added to each well. -16-
Plates were incubated at 37°C in an atmosphere containing 5% CO2 for 30 minutes.
Following this period, the reactions were terminated with the addition of NaC1 (1M) to each well. Absorbance of each wel]. was then measured on a plate reader at 405nm (FluoStar Optima, BMG Labtech, Aylesbury, U.K.).
Compound 1 in the presence of BMP-2 (lOOng/mL) was shown to induce alkaline phosphatase in murine C2C12 cells.
Induction was observable at 1mM and 500iM and the levels of alkaline phosphatase induction were over 2.2 and over 1.5 times greater than BMP-2 (lOOng/mL) alone, respectively.
Compound 2 in the presence of BMP-2 (].OOng/mL) was shown to induce alkaline phosphatase in murine C2C12 cells.
Induction was observable at 5mM and 1mM and the levels of alkaline phosphatase induction were around 1.6 and 1.1 times greater than BMP-2 (lOOng/mL) alone, respectively.
Compound 3 in the presence of BMP-2 (loOng/mL) was shown to induce alkaline phosphatase in murine C2C12 cells.
Induction was observable at 5mM and 1mM and the levels of alkaline phosphatase induction were almost 2.9 and over 1.3 times greater than BMP-2 (lOOng/mL) alone, respectively.
Assessment of mineralization in MC3T3-E.1 cells Following 14 days in treatment, cell culture experiments were washed twice in PBS and cells fixed using 2% paraformaldehyde at room temperature for 15 minutes.
Thereafter, cells were washed using deionized H20 five times. Alizarin red (40mM, p}{4.2) was added to each well for 15 minutes with gentle rocking; thereafter the stain was carefully removed and cell layers washed 5 times with deionized H20. Following these washing steps, excess I1O was carefully removed from the plates and alizarin red staining quantitatively assessed following extraction using cety].pyridinjum chloride (10% in sodium phosphate solution (10mM); pH7.0). Absorbance of each well was then measured on a plate reader at 560nm (F].uoStar Optima, BMG Labtech, Aylesbury, U.K.).
Compound 1 and compound 2 in the presence of BMP-2 (lOOng/mL) were shown to induce mineralisation in murine MC3T3-El cells. Induction was observable at 100pM and the level of mineraljsatjon was around two times greater than BMP-2 (lOOng/mL) alone.
Osterix (Osx) gPCR C2C12 cells were seeded into 6 well plates at 30,000 cells/well in DMEM medium supplemented with foetal bovine serum (10%), 1-glutamine (20mM), penicillin G (].OOpg/mL) and streptomycin (100U/mL). The following day the cells were treated with BMP-2 (lOOng/mL) and compound 1 (1mM), compound 2 (5mM) or compound 3 (5mM) and incubated for 48 hours in a humidified atmosphere containing 5% CO2 at 37°C. Therafter, cells were harvested and total RNA isolated using the RNeasy mini-kit (Qiagen #74104).
As osterix has only a single exon, to reduce contaminating effects of gDNA, On-column gDNA digestion was carried out.
First-strand cDNA was synthesised from 500ng of RNA using random hexamers and Superscript II Reverse Transcriptase (Invitrogen #18064-022). Transcript expression of Osx was determined by real-time quantitative PCR (qPCR) analysis performed in a Chromo4 Real-Time PCR detector (BioRad Laboratories) using iQ SYBR Green Supermix (BioRad #170- 8882) and the primers to detect a 124bp sequence; Primers for Osterix gPCR; 5' GTC1AGAGTCTTAGCCACTC 3'; Fwd 5' AAATGATGTGAGGCCAGATGG 3' Rev. Osx expression was normalised against 18$ ribosomal RNA expression. 1D
Compound 1 (1mM), compound 2 (5mM) and compound 3 (5mM) enhanced osterix gene expression in C2C12 cells by factors of around 266, 50 and 520, respectively, compared to BMP-2 (lOOng/mL) alone.
Example 2 -Resorbable polymer manufacturing According to one embodiment of the method of the present invention, a compound according to formula 1 is added to the polymer matrix that has been already fashioned into the form of a medical implant.
Polymer compositions are prepared by dry-mixing commercially available granular-form base materials with commercially available copolymer additives. The material composition was 80% w/w P(L/DL)LA (70/30) and 20% w/w PLLA/TMC (70/30). The components are weighed according to a desired weight ratio into a container which is then rotated in a Turbula T2F shaker mixer for 30 minutes until a homogenous dry mixture is obtained. The resulting mixture is then dried in vacuum at 60°C for 8 to 12 hours and subsequently melt-blended and injection-moulded into pieces of the desired shape. The processes and tooling required to carry out injection moulding are we].]. known to one skilled in the art of die making or plastics engineering.
Before use the plates are usually sterilized by gamma irradiation with a nominal dose of 25 kGy. After sterilisation, the plates are submerged in a solution of either compound 1, compound 2 or compound 3 for 30 seconds followed by resting at room temperature for half an hour.
Example 3 -Membrane for periodontal use The implant may also be fashioned into a barrier membrane for use in Guided Tissue Regeneration (GTR) to treat a periodontal defect.
The membrane comprises PLA/PGA-matrjx polymers. The membrane is positioned in a slot of a package, such as a plastic blister. The preparation of the membrane is conducted as one stage of surgical operation as follows: 1. After opening the package, an amount of a compound of formula I or a solution thereof is poured into the membrane slot. The membrane is fully immersed in the compound or solution thereof for an period of between seconds and 3 minutes, preferably for 30 seconds.
2. The membrane is removed from the slot.
3. The compound is allowed to diffuse into the polymer matrix of the membrane for 15 to 20 minutes.
4. The membrane is ready for use as a barrier between the gingival soft tissue and the healing bone tissue and/or periodontal tissues in order to prevent the gingival soft tissue filling the defect side.
In the conditions of a normal operating theatre temperature and humidity, the membrane stays malleable for several hours.
Implants of the invention can be used for example in guided bone regeneration applications, where the effect of an osteogenic compound loaded barrier membrane is required to avoid soft tissue ingrowth in the area where new bone formation is required, and to enhance bone regeneration.
Therapeutic applicatjon When compounds of formula I are incorporated into compositions for use in securing broken bones, it results in a more rapid healing of bones. The compounds act in a synergistic manner with BMP and other endogenous factors already present at the break site to enhance their effect on the healing process.
The compositions may be applied as a solid cast' around the portion of bone to be repaired or may be applied between two or more fractured portions as a fluid, preferably VISCOUS, so that the active compounds are present between the fractured pieces facilitating their reattachment to one another.
Compositions of the invention may be used for rebuilding bone, cosmetic surgery, trauma surgery, rebuilding fractures, and in the treatment of osteoporosis and osteosarcoma. -22 -
Claims (27)
- CLAIMS: 1. A compound according to figure I Figure I wherein R is selected from H, methyl and acety].; and X is methy].ene or ethylene; its pharmaceutically acceptable salts and prodrugs for use as a medicament.
- 2. A compound according to claim 1 wherein X is methylene and R is hydrogen or methyl.
- 3. A compound according to claim 1 wherein X is ethylene and R is acetyl.
- 4. A resorbable polymer composition comprising a polymer matrix and a compound according to any one of claims 1 to 3.
- 5. The resorbable polymer composition of claim 4 wherein the polymer matrix is selected from the group consisting of polyglycolide, polylactides, po].ycapro].actones, polytrimethylenecarbonates, polyhydroxybutyrates, polyhydroxyvale rates, polydioxanones, polyorthoesters, polycarbonateg, polytyrosinecarbonates, polyorthocarbonates polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly (maleic anhydride), polypeptides, polydepsipeptides, polyvinyla].cohol, polyesteramides, polyamides, polyanhydrides, polyurethanes, polyphosphazenes, polycyanoacrylates, polyfumarates, poly (amino acids), modified polysaccharides, modified proteins and their copolymers, terpolymers or combinations or mixtures or polymer blends thereof.
- 6. The resorbable polymer composition of claim 4 or claim wherein the polymer matrix is selected from the group consisting of polyglycolide, poly(L-lactide-co-g].ycoliae), poly(D,L-lactide-co-glycoljde), poly(L-lactide), poly(D,L-lactide), poly(L-lactide-co-D,L-lactjde), polycaprolactone, poly(L-lactide-co-caprolactone), po].y(D,L-].actide-co-caprolactone) polytrimethylenecarbonate, poly (L-lactide -co-trimethylenecarbonate) poly (D, L-].actide-co-trimethylenecarbonate), polydioxanone and their copolymers, terpolymers or combinations or mixtures or polymer blends thereof.
- 7. The resorbable polymer composition of any one of claims 4, 5 and 6 wherein the polymer matrix comprises Polylactide/Polyg1yco1ide/Trimethy1e carbonate copolymer (PLA/PGA/TMC) with a composition of 80/10/10, Po].y D, L-lactide/Poly L-lactide/Trimethy].ene carbonate copolymer (PLDLA/PLA/TMC) with a composition of 55/40/5, or a matrix comprising 80 wt-% P(L/DL)LA (70/30) and 20 wt-% PLLA/TMC (70/30)
- 8. The resorbable polymer composition of any one of claims 4 to 7 wherein the compound is present in an amount of from 0.05 to 50% by weight of the composition.
- 9. The resorbable polymer composition of claim 8 wherein the compound is present in an amount of between 0.1 and 10% by weight.
- 10. The use of a compound according to any one of claims 1 to 3 in the manufacture of a medicament for promoting osteogenesis.
- 11. The use of claim 10 wherein the promotion of osteogenesis is for treating a broken bone.
- 12. The use of claim 10 or claim 11 wherein the medicament is in the form of a resorbable polymer composition according to any one of claims 4 to 9.
- 13. A method for manufacturing an implant having osteogenic properties comprising the steps of; a) selecting polymer(s) or copolymer(s); b) adding a compound according to any one of claims 1 to 3 in an amount of between 0.05 and 50% by weight; c) processing the polymer(s) or copolymer(s) to form a polymer matrix; and d) forming the implant from said polymer matrix.
- 14 A method for manufacturing an implant having osteogenic properties comprising the steps of; a) selecting polymer(s) or copolymer(s); b) processing the polymer(s) or copolymer(s) to form a polymer matrix; C) forming the implant from said polymer matrix; and d) adding the implant to a solution of a compound according to any one of claims 1 to 3, so that an amount of between 0.05 and 50% by weight is adsorbed by the implant.
- 15. The method of claim 13 or claim 14 wherein the step of processing the polymer(s) or copolymer(s) to form a polymer matrix comprises melt processing.
- 16. The method of any one of claims 13 to 15 comprising incorporation of the compound into the polymer prior to blending and after the implant is made.
- 17. The method of any one of claims 13 to 16 wherein the polymer(s) or copolymer(s) are selected so as to provide a polymer matrix selected from the group consisting of polyglyco].ide, polylactides, polycaprolactones, polytrimethylenecarbonates, polyhydroxybutyrates, polyhydroxyvalerateg, polydioxanones, polyorthoesters, polycarbonates, polytyrosinecarbonates, polyorthocarbonates polyalkylene oxalates, polyalkylene succinates, po].y(malic acid), poly(maleic anhydride), polypeptides, polydepsipeptides, polyvinylalcohol, polyesteramides, polyamides, polyanhydrides, polyurethanes, polyphosphazenes, polycyanoacrylates, polyfumarates, poly (amino acids), modified polysaccharides, modified proteins and their copolymers, terpolymers or combinations or mixtures or polymer blends thereof.-26 -
- 18. The method of any one of claims 13 to 17 wherein the polymer(s) or copolymer(s) are selected so as to provide a polymer matrix selected from the group consisting of polyglycolide, poly(L-lactide-co-glycolicie), poly(D,L-lactide-co'-g].ycolide), poly(L-lactide), poly(D,L-lactide), poly(L-lactide-co-D,L-].actide), polycaprolactone, poly(L-lactide-co-caprolactone), poly(D, L-lactide-co-caprolactone) polytrimethylenecarbonate, po].y(L-lactide-co-trimethy].enecarbonate) po].y(D, L-lactide-co-trimethylenecarbonate), polydioxanone and their copolymers, terpolymers or combinations or mixtures or polymer blends thereof.
- 19. The method of any one of claims 13 to 16 wherein the polymer(s) or copolymer(s) are selected so as to provide a polymer matrix that comprises Polylactide/Polyglycolide/Trjmethy].ene carbonate copolymer (PLA/PGA/TMc) with a composition of 80/10/10, Poly D, t-lactide/Poly L-lactide/Trimethylene carbonate copolymer (PLDLA/PLA/TMC) with a composition of 55/40/5, or a matrix comprising 80 wt-% P(L/DL)LA (70/30) and
- 20 wt-% PLLA/TMC (70/30) 20. The method of any one of claims 13 to 19 wherein the compound is present in an amount of between 0.]. and 10% by weight.
- 2].. A method of treating a person in need thereof comprising administering a compound according to any one of 3D claims 1 to 3.-27 -
- 22. A composition comprising a compound according to any one of claims 1 to 3 and one or more of recombinant human BMP-2, BMP-4, BMI'-7 and GDF-5 in synergistically effective amounts
- 23. The resorbable polymer composition of any one of claims 4 to 9 additionally comprising one or more of recombinant human BMP-2, BMP-4, BMP-7 and GDF-5.
- 24. The use according to any one of claims 10 to 12 wherein the medicament additionally comprises one or more of recombinant human BMP-2, BMP-4, BMP-7 and GDF-5.
- 25. The method of any one of claims 13 to 20 additionally comprising the step of adding one or more of recombinant human BMP-2, BMP-4, BMP-7 and GDF-5.
- 26. A method of treating a person in need thereof comprising surgically implanting a resorbab].e polymer composition according to any one of claims 4 to 9 or claim 23.
- 27. The use of claim 10, claim 1]. or claim 24 wherein the medicament is in the form of a paste.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0714791A GB2451451A (en) | 2007-07-30 | 2007-07-30 | Osteogenic compounds |
PCT/GB2008/001923 WO2009016333A1 (en) | 2007-07-30 | 2008-06-05 | Osteogenic compounds |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0714791A GB2451451A (en) | 2007-07-30 | 2007-07-30 | Osteogenic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
GB0714791D0 GB0714791D0 (en) | 2007-09-12 |
GB2451451A true GB2451451A (en) | 2009-02-04 |
Family
ID=38528966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0714791A Withdrawn GB2451451A (en) | 2007-07-30 | 2007-07-30 | Osteogenic compounds |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB2451451A (en) |
WO (1) | WO2009016333A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
US8058237B2 (en) | 2007-08-07 | 2011-11-15 | Advanced Technologies & Regenerative Medicine, LLC | Stable composition of GDF-5 and method of storage |
EP2276458A1 (en) | 2008-04-14 | 2011-01-26 | Advanced Technologies and Regenerative Medicine, LLC | Liquid buffered gdf-5 formulations |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4396616A (en) * | 1981-09-04 | 1983-08-02 | Merck & Co., Inc. | Substituted enantholactam derivatives as antihypertensives |
EP1604693A1 (en) * | 2004-06-09 | 2005-12-14 | Scil Technology GmbH | In situ forming scaffold, its manufacturing and use |
WO2006003492A2 (en) * | 2004-07-02 | 2006-01-12 | Warner-Lambert Company Llc | Compositions and methods for treating pathological infections |
WO2006016152A1 (en) * | 2004-08-11 | 2006-02-16 | Cambridge Enterprise Limited | Anti-inflammatory agents |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6926903B2 (en) * | 2001-12-04 | 2005-08-09 | Inion Ltd. | Resorbable polymer composition, implant and method of making implant |
US7378410B2 (en) * | 2003-07-25 | 2008-05-27 | Novartis Ag | Substituted lactams and their use as anti-cancer agents |
FR2878525B1 (en) * | 2004-11-29 | 2007-02-23 | Aventis Pharma Sa | BENGAMIDES HAVING SUBSTITUTED CAPROLACTAM CYCLE, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE THEREOF |
US20060257448A1 (en) * | 2005-05-10 | 2006-11-16 | The University Of Zurich | Resorbable polymer composition, implant and method of making implant |
WO2008132458A1 (en) * | 2007-04-30 | 2008-11-06 | Inion Limited | Compositions useful in the modulation of immune responses and the treatment or prevention of inflammatory responses and related methods |
-
2007
- 2007-07-30 GB GB0714791A patent/GB2451451A/en not_active Withdrawn
-
2008
- 2008-06-05 WO PCT/GB2008/001923 patent/WO2009016333A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4396616A (en) * | 1981-09-04 | 1983-08-02 | Merck & Co., Inc. | Substituted enantholactam derivatives as antihypertensives |
EP1604693A1 (en) * | 2004-06-09 | 2005-12-14 | Scil Technology GmbH | In situ forming scaffold, its manufacturing and use |
WO2006003492A2 (en) * | 2004-07-02 | 2006-01-12 | Warner-Lambert Company Llc | Compositions and methods for treating pathological infections |
WO2006016152A1 (en) * | 2004-08-11 | 2006-02-16 | Cambridge Enterprise Limited | Anti-inflammatory agents |
Also Published As
Publication number | Publication date |
---|---|
WO2009016333A1 (en) | 2009-02-05 |
GB0714791D0 (en) | 2007-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108135702B (en) | Implants with oxysterol drug loading and methods of use | |
Lee et al. | The bone regenerative effect of platelet‐derived growth factor‐BB delivered with a chitosan/tricalcium phosphate sponge carrier | |
US8758791B2 (en) | Highly compression resistant matrix with porous skeleton | |
JPH05507930A (en) | Bone induction pharmaceutical preparation | |
US20060257448A1 (en) | Resorbable polymer composition, implant and method of making implant | |
JP2010518946A (en) | Prevention and treatment of jaw osteonecrosis and jaw radiation osteonecrosis | |
WO2008099190A2 (en) | Osteogenic compounds | |
Yonezawa et al. | Effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) on bone consolidation on distraction osteogenesis: a preliminary study in rabbit mandibles | |
JP4388483B2 (en) | Osteogenesis and / or chondrogenesis promoting agent of mesenchymal stem cells and method of promoting ossification and / or chondrogenesis | |
GB2451451A (en) | Osteogenic compounds | |
Skripitz et al. | Stimulation of implant fixation by parathyroid hormone (1–34)—a histomorphometric comparison of PMMA cement and stainless steel | |
JP2006519782A (en) | Pharmaceutical composition | |
Bravo et al. | Temporary inhibition of the plasminogen activator inhibits periosteal chondrogenesis and promotes periosteal osteogenesis during appendicular bone fracture healing | |
Nirwana et al. | Ellagic acid and hydroxyapatite promote angiogenesis marker in bone defect | |
WO2008099198A2 (en) | Osteogenic compounds | |
WO2005089699A1 (en) | Capping agent for dentinogenesis | |
Ma et al. | Inhibitory effect of nicotine on bone regeneration in mandibular distraction osteogenesis | |
Kang et al. | High-frequency, low-intensity pulsed ultrasound enhances alveolar bone healing of extraction sockets in rats: A pilot study | |
Duman et al. | Effects of gaseous ozone treatment on bone regeneration in femoral defect model in rats | |
KR100639041B1 (en) | Pharmaceutical composition for the treatment of bone fracture | |
Evans et al. | Paget's disease of bone: the effect of stopping long term human calcitonin and recommendations for future treatment | |
Tanik et al. | Investigation of the effect of combined use of alloplastic-based tricalcium phosphate bone graft and antihemorrhagic plant extract (ABS) on bone regeneration in surgically induced bone defects in nondiabetic rats: an experimental animal study | |
Niehaus et al. | Effects of orthopedic implants with a polycaprolactone polymer coating containing bone morphogenetic protein-2 on osseointegration in bones of sheep | |
Mowla et al. | Evaluation of the effect of platelet rich fibrin (PRF) on bone regeneration in the tibia of diabetic rats (histological and immunohistochemical studies) | |
Alam et al. | Relationship of tobacco smoking with Alveolar osteitis after tooth extraction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |